Browse LRBA

Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass membrane protein Endoplasmic reticulum Golgi apparatus, trans-Golgi network Lysosome
Domain PF02138 Beige/BEACH domain
PF06469 Domain of Unknown Function (DUF1088)
PF15787 Domain of unknown function (DUF4704)
PF14844 PH domain associated with Beige/BEACH
Function

May be involved in coupling signal transduction and vesicle trafficking to enable polarized secretion and/or membrane deposition of immune effector molecules.

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRBA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRBA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRBA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3830.224
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4860.683
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3120.712
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.190.576
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2820.916
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0730.983
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2440.491
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3570.821
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0730.968
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4330.716
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6120.734
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0110.875
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRBA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.22.719.50.00454
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.23.418.80.0106
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.85.917.90.197
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRBA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRBA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRBA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRBA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRBA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRBA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRBA
NameLPS-responsive vesicle trafficking, beach and anchor containing
Aliases BGL; LAB300; LBA; CDC4L; CVID8; CDC4-like protein; vesicle trafficking, beach and anchor containing; Beige-l ......
Chromosomal Location4q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRBA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.